PRDS — Pardes Biosciences Share News
0.000.00%
Last trade - 00:00HealthcareAdventurousSmall Cap
- $133.95m
- -$19.25m
Brief: Pardes Biosciences Inc Says Size Of Board Increased From Eight To Ten Directors
Brief: Pardes Biosciences Appoints Laurie Smaldone Alsup, John Pottage To Board Of Directors
Brief: Pardes Biosciences Announces Commencement Of Phase 2 Trial Evaluating PBI-0451 For The Treatment Of SARS-CoV-2 Infections
Brief: Pardes Biosciences reports Q2 results
Brief: Pardes Biosciences Says FDA Granted Fast Track Designation For PBI-0451
Enough room for next-gen COVID antiviral drugs - SVB Leerink
Brief: Pardes Biosciences Says Board Appointed Thomas G. Wiggans As Company's CFO
Brief: Pardes Biosciences Appoints Thomas G. Wiggans To CEO And Chairman Of The Board
Pardes up as COVID pill shows promise in early trial
Brief: Pardes Biosciences Presents Interim Clinical Data From Ongoing PBI-0451 Phase 1 Trial
Pardes expects to start larger trial of COVID-19 antiviral pill by mid-year
Brief: Pardes Biosciences Presents Interim Data From Phase 1 Trial Of Pbi-0451 As A Stand-Alone Oral Regimen For Covid-19
Brief: Pardes Biosciences Announces FDA Clearance Of IND Application For PBI-0451
Pardes Biosciences rises after positive data from Pfizer's COVID-19 pill
Pardes to go public, says COVID-19 antiviral pill does not need booster (updated)
Pardes to go public, says COVID-19 antiviral pill does not need booster
Brief: Pardes Biosciences Initiates First-In-Human Trial For Drug To Treat SARS-CoV-2 Infections
Brief: Pardes Biosciences And FS Development Corp. II Announce Merger Agreement
NASDAQ TRADE HALT REASON NOT AVAILABLE AT 04:00 AM